209 related articles for article (PubMed ID: 38292040)
1. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.
Mazzotta V; Lepri AC; Matusali G; Cimini E; Piselli P; Aguglia C; Lanini S; Colavita F; Notari S; Oliva A; Meschi S; Casetti R; Mondillo V; Vergori A; Bettini A; Grassi G; Pinnetti C; Lapa D; Tartaglia E; Gallì P; Mondi A; Montagnari G; Gagliardini R; Nicastri E; Lichtner M; Sarmati L; Tamburrini E; Mastroianni C; Stingone C; Siddu A; Barca A; Fontana C; Agrati C; Girardi E; Vaia F; Maggi F; Antinori A;
EClinicalMedicine; 2024 Feb; 68():102420. PubMed ID: 38292040
[TBL] [Abstract][Full Text] [Related]
2. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.
Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM
Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
6. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.
Ishola D; Manno D; Afolabi MO; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Leyssen M; Greenwood B; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):97-109. PubMed ID: 34529963
[TBL] [Abstract][Full Text] [Related]
7. Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study.
Muller MP; Navarro C; Wilson SE; Shulha HP; Naus M; Lim G; Padhi S; McGeer A; Finkelstein M; Liddy A; Bettinger JA;
Vaccine; 2024 Jan; 42(3):535-540. PubMed ID: 38199921
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
[TBL] [Abstract][Full Text] [Related]
11. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.
Hubert M; Guivel-Benhassine F; Bruel T; Porrot F; Planas D; Vanhomwegen J; Wiedemann A; Burrel S; Marot S; Palich R; Monsel G; Diombera H; Gallien S; Lopez-Zaragoza JL; Vindrios W; Taieb F; Fernandes-Pellerin S; Delhaye M; Laude H; Arowas L; Ungeheuer MN; Hocqueloux L; Pourcher V; Prazuck T; Marcelin AG; Lelièvre JD; Batéjat C; Lévy Y; Manuguerra JC; Schwartz O
Cell Host Microbe; 2023 Jun; 31(6):937-948.e4. PubMed ID: 37196656
[TBL] [Abstract][Full Text] [Related]
12. Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV.
Raccagni AR; Diotallevi S; Lolatto R; Lucente MF; Candela C; Gianotti N; Trentacapilli B; Canetti D; Castagna A; Nozza S
AIDS; 2023 Dec; 37(15):2365-2369. PubMed ID: 37773029
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.
Afolabi MO; Ishola D; Manno D; Keshinro B; Bockstal V; Rogers B; Owusu-Kyei K; Serry-Bangura A; Swaray I; Lowe B; Kowuor D; Baiden F; Mooney T; Smout E; Köhn B; Otieno GT; Jusu M; Foster J; Samai M; Deen GF; Larson H; Lees S; Goldstein N; Gallagher KE; Gaddah A; Heerwegh D; Callendret B; Luhn K; Robinson C; Greenwood B; Leyssen M; Douoguih M; Leigh B; Watson-Jones D;
Lancet Infect Dis; 2022 Jan; 22(1):110-122. PubMed ID: 34529962
[TBL] [Abstract][Full Text] [Related]
15. The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study.
Wang Y; Qiao Y; Huo Y; Wang L; Liang S; Yu M; Lan X; Song M; Zhang X; Yan Y; Xu J
Front Immunol; 2023; 14():1129651. PubMed ID: 36993947
[TBL] [Abstract][Full Text] [Related]
16. Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
Grüner E; Grossegesse M; Stern D; Ober V; Eser TM; Reiling G; Stirner R; Ibarra G; Postel N; Conca R; Dächert C; Grifoni A; Sette A; Bogner J; Seybold U; Roider J
J Infect Dis; 2024 Mar; ():. PubMed ID: 38478746
[TBL] [Abstract][Full Text] [Related]
17. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
Ilchmann H; Samy N; Reichhardt D; Schmidt D; Powell JD; Meyer TPH; Silbernagl G; Nichols R; Weidenthaler H; De Moerlooze L; Chen L; Chaplin P
J Infect Dis; 2023 May; 227(10):1203-1213. PubMed ID: 36408618
[TBL] [Abstract][Full Text] [Related]
18. Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV.
Wu S; Zou S; Ming F; Wu M; Guo W; Xing Z; Zhang Z; Liu J; Tang W; Liang K
BMC Infect Dis; 2023 Jan; 23(1):34. PubMed ID: 36670363
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
